Drug Profile

Research programme: bone morphogenetic protein type-1 receptor antagonist - La Jolla Pharmaceutical/Vanderbilt University

Alternative Names: BMP type-I receptor antagonist - La Jolla Pharmaceutical/Vanderbilt University

Latest Information Update: 13 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Fibrodysplasia ossificans progressiva
New Molecular Entity Yes

Discontinued Fibrodysplasia ossificans progressiva; Musculoskeletal disorders

13 Mar 2025 Discontinued for Fibrodysplasia ossificans progressiva in USA (unspecified route)
13 Mar 2025 Discontinued for Musculoskeletal disorders in USA (unspecified route)
22 Aug 2022 La Jolla Pharmaceutical Company has been acquired by Innoviva

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com